Edoxaban
Anticoagulant medication / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Edoxaban?
Summarize this article for a 10 year old
Edoxaban, sold under the brand name Lixiana among others, is an anticoagulant medication and a direct factor Xa inhibitor.[3] It is taken by mouth.[3]
Clinical data | |
---|---|
Trade names | Savaysa, Lixiana, Roteas, others |
Other names | DU-176b |
AHFS/Drugs.com | Monograph |
MedlinePlus | a614055 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 62%; Tmax 1–2 hours[6] |
Protein binding | 55%[6] |
Metabolism | minimal CES1, CYP3A4/5, hydrolysis, glucuronidation[6] |
Elimination half-life | 10–14 hours[6] |
Excretion | 62% feces, 35% urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C24H30ClN7O4S |
Molar mass | 548.06 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Compared with warfarin it has fewer drug interactions.[6]
It was developed by Daiichi Sankyo and approved in July 2011, in Japan for prevention of venous thromboembolisms following lower-limb orthopedic surgery.[7] It was also approved in the United States by the Food and Drug Administration (FDA) in January 2015, for the prevention of stroke and non–central-nervous-system systemic embolism.[8][9] It was approved for use in the European Union in June 2015.[4] It is on the World Health Organization's List of Essential Medicines.[10]